Navigation Links
Sofie Biosciences is Awarded a DOE Phase I SBIR to Commercialize Microscale Radiochemistry Platform
Date:7/7/2011

CULVER CITY, Calif., July 7, 2011 /PRNewswire/ -- Sofie Biosciences, developer of molecular imaging systems and probes, has been awarded a 2011 Phase I Small Business Innovation Research grant from the Department of Energy. Of the 2,163 applications received in response to their funding notice, only 197 were selected to receive Phase I grants.

(Logo: http://photos.prnewswire.com/prnh/20101208/LA13841LOGO)

Positron Emission Tomography (PET) is a molecular imaging modality that utilizes radio labeled molecules ("probes") to target and measure biological processes. Basic scientists can use the same probes to examine cells and mice as they do in patients to visualize and characterize the biology of disease, monitor its progression, and evaluate therapeutic efficacy. Over 1,600 PET probes have been developed to help answer a variety of biological questions, but only the glucose analog ([18F]FDG) is routinely used. This limitation exists because of the centralized radio pharmacy approach to PET probe production, with its complexity, high infrastructure cost, and necessity of specialized equipment and skilled personnel.

A decentralized approach to PET probe development is essential to give scientists and clinicians the freedom to determine what probes they want to use to solve the problems of their interest. This goal can be achieved by building a benchtop, PC-controlled, microscale chip-based commercial device for the on-demand production of PET probes, as is the focus of the grant.

"Winning this award enables our company to further accelerate the development of a truly disruptive technology that will allow researchers and physicians to make whatever PET probe they desire, onsite, and in a cost effective fashion," said Patrick Phelps, Sofie's President and CEO.

Creating a point-of-research/point-of-care distribution model is a transformational solution that empowers scientists and clinicians to control the development and use of PET probes as an alternative to the well-established centralized model.  Sofie's line of molecular imaging systems, radiochemistry modules, and probes enable PET to be more widely accessible, cost-effective, and convenient for integration into a variety of labs.  

About Sofie Biosciences 

Sofie is combining new PET imaging agents with innovative imaging systems to provide researchers and physicians with tools to better investigate the biology of disease. By empowering a wide array of people with valuable, translational imaging tools, Sofie is making PET scans more accessible and increasing the diversity of its applications.

For additional information contact Dr. Jennifer Cho at 424.223.6948 or jennifer.cho@sofiebio.com.


'/>"/>
SOURCE Sofie Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SANYO and BD Biosciences Collaborate to Offer Researchers Valuable Technology and Research Tools
2. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
3. Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
4. Avantra Biosciences Announces Significant Reduction In Multiplex Immunoassay Processing Time
5. Avantra Biosciences Announces the Launch of a Rapid Assay Prototyping Service
6. GeneLink Biosciences Expands its Scientific Advisory Board to Support New Product Lines
7. Ardea Biosciences to Present at Upcoming Investor Conferences
8. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
9. Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum
10. TEI Biosciences Wins SBANE 2011 New England Innovation Award
11. Transposagens piggyBac™ Vectors to be Distributed by System Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):